Toronto, November 3, 2021 (Global News Service)-Entourage Health Corp. (formerly WeedMD Inc.) (TSX-V: ENTG) (OTCQX: ETRGF) (FSE: 4WE) ("Entourage" or "Company ") The Canadian producer and distributor of award-winning cannabis products and brands is pleased to announce that it has strengthened its executive team chain through key strategic appointments in the areas of commercial sales, marketing and business development, as well as product development, cultivation and supply. At the same time that the company recently completed the acquisition of the well-known craftsman CannTx Life Sciences Inc. ("CannTx"), Entourage announced the following:
Joseph Mele is appointed Chief Commercial Officer. Joseph, who recently served as Senior Vice President of Commercial Sales and Marketing at Entourage, is responsible for overseeing all revenue-generating business roles and activities. Under his leadership, Entourage has increased sales of adult products and medical products by more than 150%, and his team has increased its brand's market share by more than 75% in the past year. Joseph also leads the business development team.
Pat Scanlon, the co-founder of CannTx, was appointed as the head of training for all the company's websites. Pat has more than 15 years of experience in flower cultivation and commercial greenhouse operations. He is good at craft-level cultivation, production and phenotypic analysis. As Entourage hopes to expand its craft cannabis business and product development, Pat will oversee the company's genetics activities and introduce new cultivars and craft practices.
James Afara was appointed as Vice President of Strategic Procurement. Former COO of CannTx, James has extensive experience in supply chain, business analysis and operations management. As a professional engineer, he brings a strong industry indicator analysis and supplier relationship, which will become an indispensable part of Entourage's expansion capabilities.
"As we complete the final integration steps with CannTx, it is vital that we continue to build a strong cohesive team supported by proven leadership to execute and achieve our strategic growth goals-I am happy to announce the appointment Joe, Pat and James," said George Scorsis, Interim CEO and Executive Chairman of Entourage. "At the critical moment of our business transformation, this expert team will further strengthen our leadership team. We are making our product pipeline through new genes, new product forms, new supply chain partners, and a strong sales and distribution network. Diversification, which will expand the reach of our Color Cannabis, Saturday Cannabis, Starseed Medicinal, and craft brands, thereby driving synergies across the organization. Royal City of Canada Cannabis Company. Entourage's revenue has been continuous in the past four reporting quarters Growth, the team will ensure that we continue to drive further growth in value and scale."
At this time, Entourage also thanked Jason Alexander, former Chief Strategy Officer and Chief Legal Officer, who played an important role in the company's acquisition of Starseed Holdings Inc. ("Starseed") and CannTx and Entourage's growth and success in the past year. Jason has chosen to resign from the management team, but the company is pleased to confirm that he will continue to serve as a director of the board of directors and head of the governance committee.
Additional information about Entourage's current management team can be found here. Visit Entourage Health's newly launched website here. To access our corporate videos, please visit us here and our latest investor presentations and corporate videos here.
Entourage Health Corp. (formerly WeedMD Inc.) is the listed parent company of WeedMD RX Inc. and CannTx Life Sciences Inc., which manufacture and distribute cannabis products for the medical and adult markets. The company owns and operates 158 acres of state-of-the-art greenhouse, outdoor and processing facilities in Strathroy, Ontario, and a fully licensed 26,000 square foot Aylmer, Ontario processing facility that specializes in cannabis extraction. With the addition of the medical-centric brand Starseed Medicinal, Entourage has expanded its multi-channel distribution strategy. Starseed's industry-first exclusive partnership with LiUNA, Canada's largest construction union, and employer and union groups complements Entourage's direct sales to medical patients. In October 2021, Entourage completed the acquisition of process grower CannTx Life Sciences Inc., which operates a state-of-the-art micropropagation and specialized extraction facility in Guelph, Ontario. Craft brand Royal City Cannabis is added to Entourage's elite product portfolio, which includes adult-use brands Color Cannabis and Saturday Cannabis-sold in eight provincial distribution agencies. The company also maintains a strategic relationship with Shoppers Drug Mart in the elderly market and supply agreements. It is the exclusive Canadian producer and distributor of the award-winning American health brand Mary's Medicinals, which is sold in medical and adult use channels. Entourage recently announced an exclusive partnership with a subsidiary of the Boston Beer Company to launch cannabis-infused beverages in Canada. It is expected to be produced in the fourth quarter of 2021 and launch products in early 2022.
For more information, please visit our website www.entouragehealthcorp.com
Follow Entourage and its brand on LinkedIn
Twitter: Entourage, Colored Cannabis, Saturday Cannabis, Interstellar Seeds and Royal City Cannabis Company.
Instagram: Entourage, Colored Cannabis, Saturday Cannabis, Interstellar Seeds and Royal City Cannabis Company.
For more information, please contact:
Investor Advisory: Valter Pinto Managing Director KCSA Strategic Communication 1-212-896-1254 entourage@kcsa.com
Media Inquiries: Marianella delaBarrera Senior Vice President of Communications and Corporate Affairs 416-897-6644 marianella@entouragecorp.com
Forward-looking information This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation, which is based on Entourage's current internal expectations, estimates, forecasts, assumptions and beliefs and views on future events. Forward-looking information can be identified through the use of forward-looking terms, such as "expects", "may", "may", "will", "should", "intends", "anticipates", "potential", "proposes", " "Estimate" and other similar words, including their negatives and grammatical variants, or statements that certain events or conditions "may", "will" or "will" occur, or strategic discussions.
The forward-looking information in this press release is based on management’s expectations, estimates, forecasts, assumptions, and opinions about future events that management believes to be reasonable under such circumstances. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, forecasts, goals, guidance or other statements that are not statements of fact. Forward-looking information inevitably involves known and unknown risks, including but not limited to risks related to general economic conditions; adverse industry events; loss of markets; future legislative and regulatory developments; inability to obtain sufficient capital from internal and external sources, And/or the inability to obtain sufficient capital on favorable terms; the overall situation of the Canadian cannabis industry; Entourage's ability to implement its business strategy, including the successful integration of CannTx and the execution of strategic partnerships; the COVID-19 pandemic; competition; crops Poor harvest; and other risks.
Any forward-looking information is only effective on the date of its release. Except as required by law, Entourage assumes no obligation to update or revise any forward-looking information, whether due to new information, future events or otherwise. New factors appear from time to time, and Entourage cannot predict all of them. When considering such forward-looking information, readers should keep in mind the risk factors and other cautionary statements in the SEDAR disclosure documents submitted by Entourage to the applicable Canadian securities regulators at www.sedar.com. The risk factors and other factors indicated in the disclosure document may cause actual events or results to be materially different from the events or results described in any forward-looking information.
Neither TSX VENTURE EXCHANGE nor its regulatory service provider (the term is defined in the policy of TSX VENTURE EXCHANGE) is not responsible for the adequacy or accuracy of this release
In the past year, the global chip shortage has been a strong impetus for the semiconductor industry. Today, I will focus on the three chip stocks operating in very different parts of the semiconductor market, why they are all growing, and why they can still generate greater returns next year. ASML Holding (NASDAQ: ASML) is a Dutch semiconductor equipment manufacturer.
Rivian and Lucid's stocks are rising, most of them so far under promised circumstances, but the stocks of these companies should be prepared to rise in accordance with the progress of their business.
Schiff publicly predicted the real estate crash of 2008. He was worried again.
Rivian Automotive's (NASDAQ: RIVN) hype has cooled down because the stock price of the second-largest US automaker in terms of market value has fallen by more than 25% from a high. QuantumScape (NYSE: QS) and ChargePoint (NYSE: CHPT) are two companies that have a foothold in their respective electric vehicle industry segments—not to mention their respective growth prospects . Howard Smith (QuantumScape): Investment can be about perspective, especially when studying speculative names that must grow to current valuations.
Rivian (NASDAQ: RIVN) went public last week. A company with only a few dozen sales and a market value of more than $100 billion seems to have broken the imagination of some investors. Rivian’s current output is only a few hundred, and it is difficult to see how to justify its valuation, but the market is a forward-looking mechanism, so we need to consider what Rivian will look like in the future. The company's first manufacturing plant in Norma, Illinois has a specified capacity of 150,000 vehicles, and through some upgrades, it may increase to 200,000 vehicles by 2023.
The pharmaceutical industry seems to be on track to achieve record-setting mergers and acquisitions (M&A) activity in 2022. First, both Pfizer (NYSE: PFE) and Moderna have ample cash for the new coronavirus vaccine. Third, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Gilead Sciences, Johnson & Johnson, Merck, Moderna, Pfizer and Sanofi are all expected to make additional acquisitions next year to enrich their clinical pipelines and products. combination.
The market rebound sent a mixed message that President Biden is about to make his candidate for the chairman of the Federal Reserve. Is it time to buy Rivian stock?
The toddler greets the audience and points out the SpaceX rocket
The fact that so many people are even talking about these names fully illustrates their potential movement.
It is easy to buy stocks, but it is very difficult to buy the right stocks without a time-tested strategy. So what is the best stock to buy or put on the watch list now?
In this article, we will discuss the 10 growth stocks that are worth buying today, based on billionaire Ken Fisher (Ken Fisher). If you want to skip our detailed analysis of these stocks, please go directly to the 5 best growth stocks that billionaire Ken Fisher considers today. Ken Fisher is a money manager, best-selling author and […]
Teladoc Health (NYSE: TDOC) may be somewhat polarized. First of all, the virtual care market has just started and has huge growth prospects. Secondly, in the long run, Teladoc is in the best position to succeed in this market.
Many investors want to know what to do with this new Kyndryl stock. Is this a better choice compared to the parent company IBM?
The market is pushing the Fed to respond faster, and consumer confidence has been hit hard by concerns about a lack of policy response to inflation.
Cisco Systems (NASDAQ: CSCO) announced its first-quarter results in line with management expectations. In the past few years, network veteran Cisco has been transforming its hardware business, including selling equipment that connects servers and data centers. Due to internal development and acquisitions, the company now proposes to provide software subscriptions for collaboration solutions, network security products, cloud monitoring functions, and more.
(Bloomberg)-India's pioneering digital payment startup Paytm's share price plummeted for the second consecutive day after its initial public offering of US$2.5 billion. This is one of the worst IPOs in the history of large technology companies. Most readers from Bloomberg read that New York City is building an oyster wall to withstand floods. A denser city, but at what price? Women behind historic house designs From bathrooms to fisheries, hidden inflation is spreading in Japan, the 70-year-old maverick CEO is determined to shake up Japan
After the market closed on Friday, Tesla investors got a small surprise when the electric car manufacturer disclosed another stock sale by an executive. Musk’s stock sales have become a major event for Tesla (Stock Code: TSLA) investors, requiring them to check and track the CEO’s trading activities every day. Since the polls, Musk has sold about 7.6 million shares, including shares sold for tax purposes when the management stock options expire.
In the long run, clean energy will replace carbon fuels. But there is still some way to go before that, and you can play a role on both sides of this transformation.
These stocks may be slightly hit in a bear market, but their respective businesses will quickly regain their favor when conditions are good.
Brookfield Renewable's dividend yield of more than 3% is also very attractive. My Motley Fool colleague Jason Hall recently named Brookfield Renewable as the strongest renewable energy stock you can own.